Blueprint Medicines — Corporate Update (April 2020)
8 slides from Blueprint Medicines's corporate update, Apr 28, 2020
Slide 1: VOYAGER clinical trial top-line results
VOYAGER clinical trial top-line results APRIL 28, 2020 CONFERENCE CALL © 2020 Blueprint Medicines Corporation
Slide 2: Forward-looking statements
Forward-looking statements 2 This presentation contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995, as amended. The words "aim," "may," "will," "could," "would," "should," "expect," "plan," "anticipate," "intend," "believe," "estimate," "predict," "
Slide 3: VOYAGER trial top-line results conference call
VOYAGER trial top-line results conference call Introductory remarks Jeff Albers, Chief Executive Officer Summary of top-line VOYAGER trial data Andy Boral, MD, PhD, Chief Medical Officer Q&A 3
Slide 4: VOYAGER was a well-designed and well-conducted clinical trial
VOYAGER was a well-designed and well-conducted clinical trial 4 Avapritinib (n = ~230) 300 mg once daily Regorafenib (n = ~230) 160 mg once daily for 3 out of every 4 weeks 3L or 4L Advanced GIST Randomized, 1:1 N = ~460 Design • Randomized, phase 3 clinical trial Eligibility • Adults with metastati
Slide 5: VOYAGER did not meet the primary endpoint
VOYAGER did not meet the primary endpoint AE, adverse event; ORR, overall response rate; mPFS, median progression-free survival. 5 Avapritinib (n=240) Regorafenib (n=236) mPFS 4.2 months 5.6 months ORR 17% 7% TOP-LINE EFFICACY • Difference in mPFS between avapritinib and regorafenib was not statisti
Slide 6: Summary and next steps for the avapritinib program in advanced GIST
Summary and next steps for the avapritinib program in advanced GIST • Avapritinib did not demonstrate an improvement in mPFS over regorafenib in 3L or 4L GIST – Efficacy results highlight the complexity of treatment-resistant advanced GIST • Top-line safety results for avapritinib were consistent wi
Slide 7: Portfolio opportunities in systemic mastocytosis and RET-altered cancers remain our priorities
Portfolio opportunities in systemic mastocytosis and RET-altered cancers remain our priorities, with multiple planned regulatory submissions in 2020 1. Includes estimated net proceeds of $308.4M from January 2020 follow-on public offering and anticipated product revenues. Excludes any potential opti
Slide 8: (Sbwuepriat.
(Sbwuepriat.